139 related articles for article (PubMed ID: 15704108)
1. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
Saito S; Egawa S; Endoh M; Ueno S; Ito A; Numahata K; Satoh M; Kuwao S; Baba S; Hakomori S; Arai Y
Int J Cancer; 2005 May; 115(1):105-13. PubMed ID: 15704108
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer.
Saito S; Murayama Y; Pan Y; Taima T; Fujimura T; Murayama K; Sadilek M; Egawa S; Ueno S; Ito A; Ishidoya S; Nakagawa H; Kato M; Satoh M; Endoh M; Arai Y
Int J Cancer; 2008 Aug; 123(3):633-40. PubMed ID: 18464263
[TBL] [Abstract][Full Text] [Related]
3. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
[TBL] [Abstract][Full Text] [Related]
4. Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.
Kankavi O; Baykara M; Eren Karanis MI; Bassorgun CI; Ergin H; Ciftcioglu MA
Ren Fail; 2014 Mar; 36(2):258-65. PubMed ID: 24168624
[TBL] [Abstract][Full Text] [Related]
5. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases.
Hull D; Ma J; Singh H; Hossain D; Qian J; Bostwick DG
BJU Int; 2009 Oct; 104(7):915-8. PubMed ID: 19388995
[TBL] [Abstract][Full Text] [Related]
6. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
9. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
13. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
14. EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer.
Takahashi S; Urano T; Tsuchiya F; Fujimura T; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
Int J Cancer; 2003 Sep; 106(3):310-5. PubMed ID: 12845666
[TBL] [Abstract][Full Text] [Related]
15. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
16. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
17. Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.
Mills J; Oliver A; Sherwin JC; Frydenberg M; Peters JS; Costello A; Harewood L; Love C; Redgrave N; van Golen KL; Bailey M; Pedersen J
Pathology; 2012 Oct; 44(6):513-8. PubMed ID: 22935975
[TBL] [Abstract][Full Text] [Related]
18. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
[TBL] [Abstract][Full Text] [Related]
19. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]